Capital Fund Management (CFM)’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$35.3M Sell
71,088
-51,846
-42% -$23M 0.16% 145
2026
Q1
$54.9M Buy
+122,934
New +$57.3M 0.25% 63
2024
Q2
Sell
-61,530
Closed -$25.7M 2193
2024
Q1
$25.7M Buy
+61,530
New +$26M 0.07% 347
2021
Q2
Sell
-17,577
Closed -$3.78M 1676
2021
Q1
$3.78M Sell
17,577
-36,888
-68% -$8.1M 0.04% 515
2020
Q4
$12.9M Sell
54,465
-13,651
-20% -$3.13M 0.12% 204
2020
Q3
$18.5M Buy
68,116
+48,783
+252% +$13.5M 0.23% 123
2020
Q2
$5.61M Buy
+19,333
New +$5.24M 0.09% 282
2020
Q1
Sell
-10,432
Closed -$2.39M 2062
2019
Q4
$2.28M Buy
+10,432
New +$2.11M 0.02% 792
2019
Q2
Sell
-13,413
Closed -$2.47M 1951
2019
Q1
$2.47M Sell
13,413
-62,323
-82% -$11.5M 0.02% 730
2018
Q4
$12.6M Buy
75,736
+6,072
+9% +$1.05M 0.11% 244
2018
Q3
$13.4M Sell
69,664
-43,864
-39% -$7.81M 0.07% 381
2018
Q2
$19.3M Buy
113,528
+62,300
+122% +$9.66M 0.1% 285
2018
Q1
$8.35M Sell
51,228
-167,638
-77% -$27.4M 0.05% 497
2017
Q4
$32.8M Buy
218,866
+56,700
+35% +$8.4M 0.18% 137
2017
Q3
$24.7M Buy
162,166
+118,400
+271% +$17.8M 0.18% 163
2017
Q2
$5.64M Buy
43,766
+6,487
+17% +$781K 0.05% 438
2017
Q1
$4.08M Buy
+37,279
New +$3.28M 0.03% 549
2016
Q4
Sell
-63,578
Closed -$5.54M 1876
2016
Q3
$5.54M Buy
63,578
+50,779
+397% +$4.8M 0.05% 434
2016
Q2
$1.1M Buy
+12,799
New +$1.11M 0.01% 928
2016
Q1
Sell
-195,893
Closed -$24.6M 1875
2015
Q4
$24.6M Sell
195,893
-83,252
-30% -$10.1M 0.25% 100
2015
Q3
$29.1M Buy
279,145
+247,180
+773% +$31.8M 0.33% 67
2015
Q2
$3.95M Buy
+31,965
New +$4.03M 0.05% 432
2015
Q1
Sell
-21,162
Closed -$2.51M 1758
2014
Q4
$2.51M Buy
21,162
+10,168
+92% +$1.15M 0.03% 627
2014
Q3
$1.24M Buy
+10,994
New +$1.05M 0.01% 846
2013
Q3
Sell
-14,791
Closed -$1.18M 1924
2013
Q2
$1.18M Buy
+14,791
New +$1.09M 0.02% 758

Other funds holding VRTX

Capital Fund Management (CFM)'s VRTX Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Vertex Pharmaceuticals (VRTX) stake by 42% in Q2 2026, selling an estimated $23M and leaving 71,088 shares worth $35.3M. The position accounts for 0.16% of the portfolio, ranked #145.

Capital Fund Management (CFM) first reported a position in VRTX in Q2 2013 and has held it in 25 quarters since. The position peaked at $54.9M in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Capital Fund Management (CFM) held 71,088 shares of Vertex Pharmaceuticals worth $35.3M as of Q2 2026.
  • Capital Fund Management (CFM) sold 51,846 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23M.
  • Vertex Pharmaceuticals made up 0.16% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #145 holding.
  • Capital Fund Management (CFM) first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 25 quarters since.
  • Capital Fund Management (CFM)'s Vertex Pharmaceuticals position peaked at $54.9M in Q1 2026.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.